BSE filing, NSE: SUVEN. Summary written from the filing by ALFA Finder's alert engine.
Suven Life Sciences Ltd: key numbers
- Share price
- ₹268.05
- Market cap
- ₹7,574 Cr
- Revenue (annual)
- ₹7.11 Cr
- Net profit (annual)
- ₹-276.3 Cr
- P/E (TTM)
- -21.5×Sector 52.0×
- Promoter holding
- 65.47%-4.61% QoQ
- FII holding
- 0.45%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Suven Life Sciences Ltd
All →Suven Life Sciences Other Announcement
Suven Life Sciences Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, pursuant to SEBI regulations.
Suven Life Sciences Business Update
Suven Life Sciences has completed patient enrollment for its global Phase-3 clinical study of Masupirdine. A total of 424 patients were randomized across the USA and Europe.
- clinical trial enrollment
- 424.0 patients
Suven Life Sciences Annual General Meeting
Suven Life Sciences held its 37th Annual General Meeting on August 25, 2026. The company submitted the proceedings, scrutineer's report, and voting results.
Suven Life Sciences Other Announcement
Suven Life Sciences Limited submitted its Monitoring Agency Report for the quarter ended June 30, 2026. The report confirms the utilization of Rs. 857.64 Crore raised via preferential issue.
- Value
- ₹857.6 Cr
Suven Life Sciences Q1 FY27 Results: Net Loss of ₹127.6 Cr, Loss Widens
Suven Life Sciences Ltd reported revenue from operations of ₹3.6 Cr (+89.5% YoY) and a net loss of ₹127.6 Cr for Q1 FY27.
- Key figure
- Net loss ₹127.6 Cr
Suven Life Sciences Board Meeting Date
Suven Life Sciences will hold a board meeting on August 6, 2026, to consider and approve its unaudited financial results for the quarter ending June 30, 2026.
Other other announcement announcements
All →Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.